Is depression the wrong treatment target for improving outcome in coronary artery disease?

Psychotherapy and Psychosomatics

Volumn 82, Issue 5, 2013, Pages 285-291

  Rafanelli, Chiara ^a   Sirri, Laura ^a   Grandi, Silvana ^a   Fava, Giovanni A ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CORONARY ARTERY DISEASE; DEPRESSION; HEART DISEASE; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TYPE A BEHAVIOR;

ANTIDEPRESSIVE AGENTS; CORONARY ARTERY DISEASE; DEPRESSIVE DISORDER; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TYPE A PERSONALITY;

EID: 84883156283     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000351586     Document Type: Review

References (91)

1. Baune BT, Stuart M, Gilmour A, Wersching H, Arolt V, Berger K: Moderators of the relationship between depression and cardiovascular disorders: A systematic review. Gen Hosp Psychiatry 2012; 34: 478-492.
2. Ladwig KH, Kieser M, König J, Breithardt G, Borggrefe M: Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J 1991; 12: 959-964.
3. Frasure-Smith N, Lespérance F, Talajic M: Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819-1825.
4. Frasure-Smith N, Lespérance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
5. Baumeister H, Hutter N, Bengel J: Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011; 9:CD008012.
6. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: A patient-level meta-analysis. JAMA 2010; 303: 47-53.
7. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M: Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701-709.
8. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA: Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 337-341.
9. Lespérance F, Frasure-Smith N, Talajic M, Bourassa MG: Five-year risk of cardiac mortality in relation to initial severity and oneyear changes in depression symptoms after myocardial infarction. Circulation 2002; 105: 1049-1053.
10. Rafanelli C, Roncuzzi R, Milaneschi Y: Minor depression as a cardiac risk factor after coronary artery bypass surgery. Psychosomatics 2006; 47: 289-295.
11. Rafanelli C, Milaneschi Y, Roncuzzi R, Pancaldi LG: Dysthymia before myocardial infarction as a cardiac risk factor at 2.5-year follow-up. Psychosomatics 2010; 51: 8-13.
12. Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM: Platelet/ endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 939-944.
13. Pacher P, Kecskemeti V: Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 2004; 10: 2463-2475.
14. Kanjanauthai S, Kanluen T, Chareonthaitawee P: Citalopram-induced torsade de pointes, a rare life-threatening side effect. Int J Cardiol 2008; 131:e33-e34.
15. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbøl EL, Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanters JK, Poulsen HE, Pehrson S, Køber L, Torp-Pedersen C: Antidepressant use and risk of out-of-hospital cardiac arrest: A nationwide case-time-control study. Clin Pharmacol Ther 2012; 92: 72-79.
16. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH: QT interval and antidepressant use: A cross-sectional study of electronic health records. BMJ 2013; 346:f288.
17. Licht CM, de Geus EJ, van Dyck R, Penninx BW: Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry 2010; 68: 861-868.
18. Licht CM, Vreeburg SA, van Reedt Dortland AK, Giltay EJ, Hoogendijk WJ, DeRijk RH, Vogelzangs N, Zitman FG, de Geus EJ, Penninx BW: Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab 2010; 95: 2458-2466.
19. Dhabali AA, Awang R, Zyoud SH: Clinically important drug-drug interactions in primary care. J Clin Pharm Ther 2012; 37: 426-430.
20. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E: Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183: 1835-1843.
21. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
22. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 3106-3116.
23. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-379.
24. Glassman AH, Bigger JT Jr: Antidepressants in coronary heart disease: SSRIs reduce depression, but do they save lives? JAMA 2007; 297: 411-412.
25. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, Watkins JT, Imber SD, Leber WR, Moyer J, Oliveri ME: Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program. Am J Psychiatry 1991; 148: 997-1008.
26. Parker G, Parker I, Brotchie H, Stuart S: Interpersonal psychotherapy for depression? The need to define its ecological niche. J Affect Disord 2006; 95: 1-11.
27. Gehi A, Haas D, Pipkin S, Whooley MA: Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005; 165: 2508-2513.
28. Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, Albanese G, Kronish I, Hegel M, Burg MM: Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med 2010; 170: 600-608.
29. Carney RM, Freedland KE: Is there a highrisk subtype of depression in patients with coronary heart disease? Curr Psychiatry Rep 2012; 14: 1-7.
30. Doyle F, Conroy R, McGee H, Delaney M: Depressive symptoms in persons with acute coronary syndrome: Specific symptom scales and prognosis. J Psychosom Res 2010; 68: 121-130.
31. de Jonge P, Ormel J, van den Brink RH, van Melle JP, Spijkerman TA, Kuijper A, van Veldhuisen DJ, van den Berg MP, Honig A, Crijns HJ, Schene AH: Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry 2006; 163: 138-144.
32. Martens EJ, Hoen PW, Mittelhaeuser M, de Jonge P, Denollet J: Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. Psychol Med 2010; 40: 807-814.
33. Roest AM, Thombs BD, Grace SL, Stewart DE, Abbey SE, de Jonge P: Somatic/affective symptoms, but not cognitive/affective symptoms, of depression after acute coronary syndrome are associated with 12-month allcause mortality. J Affect Disord 2011; 131: 158-163.
34. Bekke-Hansen S, Trockel M, Burg MM, Taylor CB: Depressive symptom dimensions and cardiac prognosis following myocardial infarction: results from the ENRICHD clinical trial. Psychol Med 2012; 42: 51-60.
35. Appels A, Mulder P: Excess fatigue as a precursor of myocardial infarction. Eur Heart J 1988; 9: 758-764.
36. Kop WJ, Appels AP, Mendes de Leon CF, de Swart HB, Bär FW: Vital exhaustion predicts new cardiac events after successful coronary angioplasty. Psychosom Med 1994; 56: 281-287.
37. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J: Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. Adults. Epidemiology 1993; 4: 285-294.
38. Everson SA, Goldberg DE, Kaplan GA, Cohen RD, Pukkala E, Tuomilehto J, Salonen JT: Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996; 58: 113-121.
39. Pedersen SS, Denollet J, Daemen J, van de Sande M, de Jaegere PT, Serruys PW, Erdman RA, van Domburg RT: Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxeleluting stents. J Psychosom Res 2007; 62: 455-461.
40. Rafanelli C, Roncuzzi R, Milaneschi Y, Tomba E, Colistro MC, Pancaldi LG, Di Pasquale G: Stressful life events, depression and demoralization as risk factors for acute coronary heart disease. Psychother Psychosom 2005; 74: 179-184.
41. Grandi S, Sirri L, Tossani E, Fava GA: Psychological characterization of demoralization in the setting of heart transplantation. J Clin Psychiatry 2011; 72: 648-654.
42. Kubzansky LD, Sparrow D, Vokonas P, Kawachi I: Is the glass half empty or half full? A prospective study of optimism and coronary heart disease in the normative aging study. Psychosom Med 2001; 63: 910-916.
43. Shen BJ, McCreary CP, Myers HF: Independent and mediated contributions of personality, coping, social support, and depressive symptoms to physical functioning outcome among patients in cardiac rehabilitation. J Behav Med 2004; 27: 39-62.
44. Larsen BA, Christenfeld NJ: Cardiovascular disease and psychiatric comorbidity: The potential role of perseverative cognition. Cardiovasc Psychiatry Neurol DOI: 10.1155/ 2009/791017.
45. Strik JJ, Denollet J, Lousberg R, Honig A: Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 2003; 42: 1801-1807.
46. Suls J, Bunde J: Anger, anxiety, and depression as risk factors for cardiovascular disease: The problems and implications of overlapping affective dispositions. Psychol Bull 2005; 131: 260-300.
47. Chida Y, Steptoe A: The association of anger and hostility with future coronary heart disease: A meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53: 936-946.
48. Janszky I, Ahnve S, Lundberg I, Hemmingsson T: Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J Am Coll Cardiol 2010; 56: 31-37.
49. Kronish IM, Chaplin WF, Rieckmann N, Burg MM, Davidson KW: The effect of enhanced depression care on anxiety symptoms in acute coronary syndrome patients: findings from the COPES trial. Psychother Psychosom 2012; 81: 245-247.
50. Denollet J, Sys SU, Brutsaert DL: Personality and mortality after myocardial infarction. Psychosom Med 1995; 57: 582-591.
51. Beutel ME, Wiltink J, Till Y, Wild PS, Münzel T, Ojeda FM, Zeller T, Schnabel RB, Lackner K, Blettner M, Zwiener I, Michal M: Type D personality as a cardiovascular risk marker in the general population: results from the Gutenberg health study. Psychother Psychosom 2012; 81: 108-117.
52. Lee HB, Bienvenu OJ, Cho SJ, Ramsey CM, Bandeen-Roche K, Eaton WW, Nestadt G: Personality disorders and traits as predictors of incident cardiovascular disease: findings from the 23-year follow-up of the Baltimore ECA study. Psychosomatics 2010; 51: 289-296.
53. Huffman JC, Celano CM, Januzzi JL: The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010; 6: 123-136.
54. Rafanelli C, Fava GA, Sonino N: Sequential treatment of depression in primary care. Int J Clin Pract 2007; 61: 1719-1729.
55. Fava GA, Tomba E: New modalities of assessment and treatment planning in depression: The sequential approach. CNS Drugs 2010; 24: 453-465.
56. Kim ES, Sun JK, Park N, Kubzansky LD, Peterson C: Purpose in life and reduced risk of myocardial infarction among older U.S. Adults with coronary heart disease: A two-year follow-up. J Behav Med 2013; 36: 124-133.
57. Ormel J, de Jonge P: Unipolar depression and the progression of coronary artery disease: Toward an integrative model. Psychother Psychosom 2011; 80: 264-274.
58. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C, Brand RJ: Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280: 2001-2007.
59. Cole JA, Smith SM, Hart N, Cupples ME: Systematic review of the effect of diet and exercise lifestyle interventions in the secondary prevention of coronary heart disease. Cardiol Res Pract 2010; 2011: 232351.
60. Janssen V, Gucht VD, Dusseldorp E, Maes S: Lifestyle modification programmes for patients with coronary heart disease: A systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2012, Epub ahead of print.
61. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129-133.
62. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW: Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975-990.
63. Ornish D: Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project. Am J Cardiol 1998; 82: 72T-76T.
64. Aldana SG, Greenlaw R, Thomas D, Salberg A, DeMordaunt T, Fellingham GW, Avins AL: The influence of an intense cardiovascular disease risk factor modification program. Prev Cardiol 2004; 7: 19-25.
65. Kappagoda CT, Ma A, Cort DA, Paumer L, Lucus D, Burns J, Amsterdam E: Cardiac event rate in a lifestyle modification program for patients with chronic coronary artery disease. Clin Cardiol 2006; 29: 317-321.
66. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svärdsudd K: Randomized controlled trial of cognitive behavioral therapy vs. standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011; 171: 134-140.
67. Rankin P, Morton DP, Diehl H, Gobble J, Morey P, Chang E: Effectiveness of a volunteerdelivered lifestyle modification program for reducing cardiovascular disease risk factors. Am J Cardiol 2012; 109: 82-86.
68. Sebregts EH, Falger PR, Bär FW: Risk factor modification through nonpharmacological interventions in patients with coronary heart disease. J Psychosom Res 2000; 48: 425-441.
69. Friedman M, Rosenman RH: Association of specific overt behavior pattern with blood and cardiovascular findings; blood cholesterol level, blood clotting time, incidence of arcus senilis, and clinical coronary artery disease. JAMA 1959; 169: 1286-1296.
70. Rozanski A, Blumenthal JA, Kaplan J: Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192-2217.
71. Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Theorell T, Wise TN: Diagnostic criteria for use in psychosomatic research. Psychother Psychosom 1995; 63: 1-8.
72. Rafanelli C, Roncuzzi R, Finos L, Tossani E, Tomba E, Mangelli L, Urbinati S, Pinelli G, Fava GA: Psychological assessment in cardiac rehabilitation. Psychother Psychosom 2003; 72: 343-349.
73. Sirri L, Fava GA: Diagnostic criteria for psychosomatic research and somatic symptom disorders. Int Rev Psychiatry 2013; 25: 19-30.
74. Sirri L, Fava GA, Guidi J, Porcelli P, Rafanelli C, Bellomo A, Grandi S, Grassi L, Pasquini P, Picardi A, Quartesan R, Rigatelli M, Sonino N: Type A behaviour: A reappraisal of its characteristics in cardiovascular disease. Int J Clin Pract 2012; 66: 854-861.
75. Barrick CB: Sad, glad, or mad hearts? Epidemiological evidence for a causal relationship between mood disorders and coronary artery disease. J Affect Disord 1999; 53: 193-201.
76. Oedegaard KJ, Neckelmann D, Fasmer OB: Type A behaviour differentiates bipolar II from unipolar depressed patients. J Affect Disord 2006; 90: 7-13.
77. Wang Y, Terao T, Hoaki N, Goto S, Tsuchiyama K, Iwata N, Yoshimura R, Nakamura J: Type A behavior pattern and hyperthymic temperament: Possible association with bipolar IV disorder. J Affect Disord 2011; 133: 22-28.
78. Fiedorowicz JG, Solomon DA, Endicott J, Leon AC, Li C, Rice JP, Coryell WH: Manic/ hypomanic symptom burden and cardiovascular mortality in bipolar disorder. Psychosom Med 2009; 71: 598-606.
79. Fiedorowicz JG, Coryell WH, Rice JP, Warren LL, Haynes WG: Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother Psychosom 2012; 81: 235-243.
80. Dubovsky SL: Treatment of bipolar depression. Psychiatr Clin North Am 2005; 28: 349-370.
81. Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306-311.
82. Sirri L, Fava GA, Sonino N: The unifying concept of illness behavior. Psychother Psychosom 2013; 82: 74-81.
83. Fava GA, Tomba E, Grandi S: The road to recovery from depression-don't drive today with yesterday's map. Psychother Psychosom 2007; 76: 260-265.
84. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, West R, Moxham T, Thompson DR, Taylor RS: Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 2011; 8:CD002902.
85. Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L, Rabin DD, Breall WS, Bourg E, Levy R, Dixon T: Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: Summary results of the recurrent coronary prevention project. Am Heart J 1986; 112: 653-665.
86. Nunes EV, Frank KA, Kornfeld DS: Psychologic treatment for the type A behavior pattern and for coronary heart disease: A metaanalysis of the literature. Psychosom Med 1987; 49: 159-173.
87. Horwitz RI, Horwitz SM: The coronaryprone behavior pattern. Achievements and missed opportunities. Arch Intern Med 1986; 146: 1429-1433.
88. Fava GA: Clinical judgment in psychiatry. Requiem or reveille? Nord J Psychiatry 2013; 67: 1-10.
89. Czarny MJ, Arthurs E, Coffie DF, Smith C, Steele RJ, Ziegelstein RC, Thombs BD: Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: A systematic review. PLoS One 2011; 6:e27671.
90. Fava GA, Rafanelli C, Tomba E: The clinical process in psychiatry: A clinimetric approach. J Clin Psychiatry 2012; 73: 177-184.
91. Tomba E, Bech P: Clinimetrics and clinical psychometrics: macro-and micro-analysis. Psychother Psychosom 2012; 81: 333-343.